Gilead Sciences, Inc. $GILD Shares Sold by Keudell Morrison Wealth Management

Keudell Morrison Wealth Management trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,919 shares of the biopharmaceutical company’s stock after selling 2,106 shares during the quarter. Keudell Morrison Wealth Management’s holdings in Gilead Sciences were worth $545,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its position in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares in the last quarter. Nuveen LLC purchased a new position in Gilead Sciences in the first quarter worth $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in Gilead Sciences in the second quarter worth $238,083,000. Los Angeles Capital Management LLC raised its position in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after acquiring an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $112.69 on Friday. The business has a 50 day moving average price of $114.34 and a 200 day moving average price of $109.94. Gilead Sciences, Inc. has a twelve month low of $83.98 and a twelve month high of $121.83. The company has a market cap of $139.83 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 0.77 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the company earned $2.01 EPS. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GILD shares. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. UBS Group raised their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Finally, Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $117.17.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares in the company, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,402,130 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.